Immune, Molecular and Genetic Profiles of Gastric Signet Ring Cell Carcinoma: Recent Progress and Future Challenges
Understanding why gastric cancer resists immunotherapy points toward combination strategies and targeted drugs (like zolbetuximab) that could improve treatment options.
This review synthesizes emerging knowledge on GSRCC's unique immune-quiescent tumor microenvironment and explains poor immunotherapy responses via CXCL13 depletion from exhausted CD8+ T cells and absent tertiary lymphoid structures. Wnt signaling drives plasticity from indolent to invasive phenotype, and CLDN18.2 targeting (zolbetuximab) represents a validated therapeutic avenue.
What the study was
- Study design
- Narrative review
- Population
- Gastric signet ring cell carcinoma patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- International Journal of Cancer
Why it surfaced
Mechanistic review clarifying GSRCC immunotherapy resistance with actionable therapeutic targets (CLDN18.2, CXCL13/CD8-Tex axis); not a clinical trial but provides pipeline-relevant mechanistic framing.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.